Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

LON/0IGA stock hub

LON/0IGA has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0IGAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

359.7M

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0IGA

In the news

Latest news · LON/0IGA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.9P50 16.9P75 23.5

Trailing P/En/a

P25 15.9P50 22.9P75 35.8

ROE-1.6

P25 -54.2P50 2.1P75 13.7

ROIC-20

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0IGA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

198

Groups with data

Currency

USD

Showing 198 of 198 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	UK
Employees	900
Employees Change	-700%
Employees Change Percent	-43.75
Enterprise value	$671.1M
Exchange	London Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	US29089Q1058
Last refreshed	2026-05-10
Market cap	$359.7M
Price	$9.43
Price currency	USD
Rev Per Employee	569,493.36x
Sector	Healthcare
Sic	2836
Symbol	lon/0IGA
Website	https://www.emergentbiosolutions.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1.81%
EV Earnings	-103.04x
EV/EBIT	12.14x
EV/EBITDA	5.49x
EV/FCF	6.54x
EV/Sales	1.35x
FCF yield	28.51%
P/B ratio	0.91x
P/S ratio	0.7x
PE Ratio10 Y	46.87x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	11.13%
EBITDA Margin	24.63%
FCF margin	20.01%
Gross margin	47.49%
Gross Profit	$243.4M
Gross Profit Growth	10.67%
Gross Profit Growth Q	-38.38%
Gross Profit Growth3 Y	26.15%
Gross Profit Growth5 Y	-19.93%
Net Income	$-6.5M
Net Income Growth Q	-90%
Net Income Growth Years	2%
Pretax Margin	0.52%
Profit Margin	-1.27%
Profit Per Employee	$-7,236
Profitable Years	1
ROA	3.43
Roa5y	1.02
ROCE	6.43
ROE	-1.6
Roe5y	-19.53
ROIC	-20.02
Roic5y	0.76

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	96.47%
Cagr3y	1.98%
Cagr5y	-30.73%
EPS Growth Q	-93.75
EPS Growth Years	2
FCF Growth	43.43%
FCF Growth5 Y	-15.29%
OCF Growth	34.42%
OCF Growth10 Y	-0.3%
OCF Growth5 Y	-21.08%
Revenue Growth	-29.89x
Revenue Growth Q	-29.75x
Revenue Growth Years	0x
Revenue Growth3 Y	-11.44x
Revenue Growth5 Y	-16.88x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.49
Assets	$999.9M
Cash	$121.4M
Current Assets	$467.7M
Current Liabilities	$109.1M
Debt	$442.7M
Debt EBITDA	$3.51
Debt Equity	$1.12
Debt FCF	$4.32
Equity	$396.1M
Interest Coverage	1.35
Liabilities	$603.8M
Long Term Assets	$532.3M
Long Term Liabilities	$494.7M
Net Cash	$-321.3M
Net Cash By Market Cap	$-89.33
Net Debt EBITDA	$2.55
Net Debt Equity	$0.81
Net Debt FCF	$3.13
Tangible Book Value	$39.9M
Tangible Book Value Per Share	$0.77
WACC	-5.18

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.29
Inventory Turnover	1.11
Net Working Capital	$250.7M
Quick ratio	1.9
Working Capital	$370.2M
Working Capital Turnover	$0.95

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.26%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	96.38%
200-day SMA	9.64
3Y total return	6.06%
50-day SMA	8.42
50-day SMA vs 200-day SMA	50under200
5Y total return	-84.05%
All Time High	121.1
All Time High Change	-92.21%
All Time High Date	2021-02-11
All Time Low	1.48
All Time Low Change	537.16%
All Time Low Date	2024-02-06
ATR	0.54
Beta	2.36
Ch YTD	-23.71
High	9.56
High52	13.91
High52 Date	2026-01-08
High52ch	-32.19%
Low	9
Low52	5.3
Low52 Date	2025-05-15
Low52ch	77.93%
Ma50ch	11.97%
Price vs 200-day SMA	-2.13%
RSI	63.18
RSI Monthly	48.69
RSI Weekly	50.69
Sharpe ratio	1.07x
Sortino ratio	2.11
Total Return	1.26%
Tr YTD	-23.71
Tr1m	21.04%
Tr1w	8.26%
Tr3m	-12.77%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$57M
Operating Income Growth Q	-79.17
Operating Income Growth5 Y	-34.02
Operating margin	11.13

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	46,949,865%
Net Borrowing	-82,520,325
Shares Insiders	2%
Shares Institutions	80.54%
Shares Qo Q	7.82%
Shares Yo Y	-1.26%
Short Ratio	11.17

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$90M
Average Volume	1,351.65x
Bv Per Share	7.65
CAPEX	$-9.5M
Ch1m	21.04
Ch1w	8.27
Ch1y	96.38
Ch3m	-12.77
Ch3y	6.05
Ch5y	-84.05
Ch6m	-4.25
Change	3.06%
Change From Open	1.84
Close	9.15
Days Gap	1.2
Depreciation Amortization	67,043,179.6
Dollar Volume	27,997.7
Earnings Date	2026-04-30
EBIT	$57M
EBITDA	$126.2M
EPS	$-0.16
F Score	5
FCF	$102.5M
FCF EV Yield	15.28x
Financing CF	-111,778,218
Fiscal Year End	December
Founded	1,998
Income Tax	$9.2M
Investing CF	5,679,788
Is Primary Listing	0
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Ma150	10.18
Ma150ch	-7.38%
Ma20	8.52
Ma20ch	10.68%
Net CF	6,588,554
Next Earnings Date	2026-08-03
Open	9.26
P FCF Ratio	3.51
P OCF Ratio	3.21
Position In Range	76.79
Ppne	153,524,480.2
Price Date	2026-05-08
Price EBITDA	$2.85
Ptbv Ratio	9.01
Relative Volume	2.36x
Revenue	512,544,024x
SBC By Revenue	2.45x
Share Based Comp	12,571,263
Tax By Revenue	1.79x
Tax Rate	345.71%
Tr6m	-4.25%
Volume	2,969
Z Score	1.33

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0IGA pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0IGA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0IGA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+80.5%

Share of float held by funds and institutions

Insider ownership

+2.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LON/0IGA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

63.2

Neutral momentum band

Price vs 200-day MA

-2.1%

50/200-day relationship not available

Beta (5Y)

2.36

More volatile than the market

Sharpe ratio

1.07

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0IGA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0IGA stock rating?

lon/0IGA is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0IGA analysis?

The full report lives at /stocks/lon/0IGA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0IGA?

The latest report frames lon/0IGA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0IGA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.